BPC-157 vs GHK-Cu

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicBPC-157GHK-Cu
What it is

A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1

A copper-binding tripeptide, a chain of three amino acids (glycyl-histidyl-lysine) bound to copper, recorded by FDA as copper tripeptide-1.4,5

FDA status

Not FDA-approved

Not an FDA-approved drug1

Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,3,6

Is BPC-157 FDA-approved?

Not FDA-approved

FDA compounding-list review for non-injectable routes2

No FDA approval is reported in the sources reviewed here. FDA lists GHK-Cu, except in injected forms, in category 1 (under evaluation) for the 503A compounding list, and lists injected GHK-Cu among withdrawn nominations with safety concerns.2,7

Is GHK-Cu FDA-approved?

HHS compounding policy, October 30, 2026

In the policy: one of the six peptides it lists.3

Not among the six peptides the policy lists.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them.3,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.7

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists injected GHK-Cu among substances whose nominations were withdrawn, citing possible immune reactions and limited human safety data.7

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study One randomized, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract. FDA found its reported details inadequate to support efficacy or safety conclusions.1
  • Small, short, or incompletely reported human study Four other small human reports listed by FDA: enema studies in healthy volunteers, knee-pain injections in 17 people, bladder injections in 12 people with interstitial cystitis, and an intravenous safety pilot in two healthy adults.1
  • Registered trial without results A randomized Phase 2 trial in adults with an acute hamstring strain, first posted in February 2026 as recruiting, with no results posted.8
  • Registered trial without results A Phase 1 study in rotator cuff tears, listed as not yet recruiting in its September 3, 2026 registry record.9
  • Animal or laboratory research Most published research reports effects in rodent and laboratory models, including gut, liver, tendon and nerve injury models.1

Smaller controlled human trials

  • Controlled human trial A multicenter, randomized, evaluator-blinded study comparing a copper-peptide gel with an inactive gel, alongside standard wound care, in people with diabetic foot ulcers. The published abstract does not give the total number of participants.5
  • Controlled human trial A small randomized study in which 13 people completed skin-care routines with or without GHK-Cu after laser skin resurfacing and were followed for 12 weeks.10
Records collected

1 ClinicalTrials.gov record and 49 PubMed records collected

0 ClinicalTrials.gov records and 17 PubMed records collected

Area of study

Gut and digestion, Tissue repair and wound healing1,8

Skin, Tissue repair and wound healing

Latest dated events
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists BPC-157 among six peptide substances used in compounding.3,6
  2. FDA’s Pharmacy Compounding Advisory Committee discusses BPC-157.11
  3. FDA staff date their evaluation recommending that BPC-157 not be added to the 503A bulks list.1
  1. FDA restores GHK-Cu, except in injected forms, to category 1 of its 503A nominations list.2
  2. FDA removes GHK-Cu from category 1 after nominations are withdrawn, and its safety-risk page lists injected GHK-Cu among withdrawn nominations.2,7
  3. Results of a small randomized study of GHK-Cu skin care after laser resurfacing are published.10

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA briefing document for BPC-157-related bulk drug substances ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  3. 3
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    Copper tripeptide-1 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  5. 5
    Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (1994) · PMID 17147644 ↗

    Wound Repair and Regeneration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  8. 8
    BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  9. 9
    ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026

  10. 10
    Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006) · PMID 16847171 ↗

    Archives of Facial Plastic Surgery · Official source · Source checked November 14, 2026

  11. 11
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026